| Title |
Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study
|
|---|---|
| Published in |
Frontiers in Pharmacology, June 2020
|
| DOI | 10.3389/fphar.2020.00857 |
| Pubmed ID | |
| Authors |
Valentina Giudice, Pasquale Pagliano, Alessandro Vatrella, Alfonso Masullo, Sergio Poto, Benedetto Maria Polverino, Renato Gammaldi, Angelantonio Maglio, Carmine Sellitto, Carolina Vitale, Bianca Serio, Bianca Cuffa, Anna Borrelli, Carmine Vecchione, Amelia Filippelli, Carmine Selleri |
X Demographics
The data shown below were collected from the profiles of 49 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 13 | 27% |
| Italy | 2 | 4% |
| Austria | 1 | 2% |
| Unknown | 33 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 47 | 96% |
| Scientists | 2 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 127 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 127 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 18 | 14% |
| Other | 15 | 12% |
| Researcher | 14 | 11% |
| Professor > Associate Professor | 7 | 6% |
| Student > Ph. D. Student | 6 | 5% |
| Other | 24 | 19% |
| Unknown | 43 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 39 | 31% |
| Agricultural and Biological Sciences | 7 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 6% |
| Biochemistry, Genetics and Molecular Biology | 4 | 3% |
| Nursing and Health Professions | 3 | 2% |
| Other | 21 | 17% |
| Unknown | 46 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 30. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 April 2021.
All research outputs
#1,354,489
of 25,998,826 outputs
Outputs from Frontiers in Pharmacology
#512
of 20,004 outputs
Outputs of similar age
#39,281
of 436,116 outputs
Outputs of similar age from Frontiers in Pharmacology
#15
of 501 outputs
Altmetric has tracked 25,998,826 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 20,004 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 436,116 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 501 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.